Cellectar
Florham Park, New Jersey, United States · Biopharma, Biotechnology, Healthcare
Cellectar Biosciences is focused on the discovery and development of drugs for the treatment of cancer. The company is developing proprietary drugs independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop PDCs that specifically target cancer cells, delivering improv
Key facts
- Headquarters
- Florham Park, New Jersey, United States
- Employees
- Unknown
- Industries
- Biopharma, Biotechnology, Healthcare
- Status
- Public (CLRB)
- Website
- cellectar.com
- Company page
Recent activity at Cellectar
- : SEC 8-K (2.02): On May 14, 2026, Cellectar Biosciences, Inc. announced its financial results for the quarter ended March 31, 2026, via a press release. This update included detailed information on their operations and financial condition, reflecting on key metrics and performance during the first quarter of the fiscal year. The press release aims to inform shareholders and the market of the company's current standing and future outlook. The event date was significant for investors analyzing the company's financial health and trajectory in the biopharmaceutical industry.
- : Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225
- : Cellectar Biosciences
- : Cellectar Biosciences Announces Closing Of Up To Approximately $103 Million Private Placement Financing
- : Cellectar Biosciences Announces Up To Approximately $103 Million Private Placement Financing
- : Cellectar Biosciences, Inc.
- : Cellectar Biosciences, Inc.
Cellectar funding history
| Date | Round | Amount |
|---|---|---|
| Sep 2023 | Venture | $24.5M |
| Sep 2023 | Post-IPO Equity | $103.0M |
| Sep 2023 | Post-IPO Equity | $103.0M |
| Jan 2021 | Venture | $20.5M |
| May 2019 | Venture | $5.0M |
Leadership
- James Caruso, Executive Officer, Director
- Frederick Driscoll, Director
- Stephen Hill, Director
- Stefan Loren, Director
- John Neis, Director
- Douglas Swirsky, Director
- John Friend, Director
Verified email and direct lines for Cellectar’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Cellectar files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Cellectar in the news
- Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Tuesday, November 10, 2026 - Yahoo Finance Singapore (Nov 02, 2026)
- Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026 - Investing News Network (May 14, 2026)
- Cellectar Biosciences Reports Case Study Highlighting - GlobeNewswire (Oct 27, 2026)
- One lymphoma patient had no disease progression for over eight years after one treatment. - Stock Titan (Oct 27, 2026)
- Cellectar Biosciences (CLRB) Upgraded to Buy: Here's What You Should Know - Yahoo Finance (May 07, 2026)
- Cancer treatment responses lasted a median 16 months in Cellectar's study - Stock Titan (Oct 15, 2026)
- Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Workshop for Waldenström Macroglobulinemia - GlobeNewswire (Oct 15, 2026)
- Cellectar Biosciences to Present Compelling Efficacy Data from Phase 2 CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Refractory/Resistant to BTK Inhibitor Therapy at International Workshop for Waldenström Macroglobulinemia - GlobeNewswire (Sep 29, 2026)
Companies similar to Cellectar
- Citius Pharmaceuticals, Inc. · Biopharma, Biotechnology, Healthcare, Pharmaceutical
- ISOThrive · Biopharma, Biotechnology, Healthcare, Pharmaceutical
- Longboard Pharmaceuticals · Biopharma, Biotechnology, Healthcare, Pharmaceutical
- Arbutus · Biopharma, Biotechnology, Healthcare, Pharmaceutical
- Milestone Pharmaceuticals · Biopharma, Biotechnology, Healthcare, Pharmaceutical
About Cellectar: questions and answers
What does Cellectar do?
Cellectar Biosciences is focused on the discovery and development of drugs for the treatment of cancer. The company is developing proprietary drugs independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop PDCs that specifically target cancer cells, delivering improv
Where is Cellectar headquartered?
Cellectar is headquartered in Florham Park, New Jersey, United States.
Has Cellectar raised funding?
Yes. Fundz has recorded 5 funding events for Cellectar. The most recent, $24.5M, was in Sep 2023.
What is the latest news on Cellectar?
On May 14, 2026, SEC 8-K (2.02): On May 14, 2026, Cellectar Biosciences, Inc. announced its financial results for the quarter ended March 31, 2026, via a press release. This update included detailed information on their operations and financial condition, reflecting on key metrics and performance during the first qu
Is Cellectar a public company?
Yes. Cellectar is publicly traded under the ticker CLRB.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy